SavedAdd your journal

Journals / ENT Updates / 2013 / Cilt: 3 Sayı: 3

Prognosis in head and neck cancer: the importance of the patient-, and treatment-related factors

Baş boyun kanserlerinde prognoz: Hasta ve tedaviyle ilişkili faktörlerin önemi

Birsen Yücel
Mehmet Fuat Eren
Ebru Akkaş Atesever
Turgut Kaçan
Zekiye Hasbek
Mehmet Metin Şeker
Pages
109–115
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The 3-year local control, overall survival and disease-free survival rates were 72%, 59%, and 53%, respectively for all patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the importance of comorbidity, performance status, hemoglobin level, weight loss, interruption of radiotherapy, and mucositis as prognostic factors in head and neck cancer patients.
📊
Key Findings & Data:Methods: Two-hundred and ten patients who were admitted to the Oncology Center of our university between 2006 and 2012, and treated for head and neck cancer were included in the study.
💡
Conclusion & Impact:The 3-year local control, overall survival and disease-free survival rates were 72%, 59%, and 53%, respectively for all patients.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Baş boyun kanseri · kilo kaybı · hemoglobin

Abstract

Objective: To investigate the importance of comorbidity, performance status, hemoglobin level, weight loss, interruption of radiotherapy, and mucositis as prognostic factors in head and neck cancer patients. Methods: Two-hundred and ten patients who were admitted to the Oncology Center of our university between 2006 and 2012, and treated for head and neck cancer were included in the study. Performance status at admission was evaluated according to Eastern Cooperative Oncology Group (ECOG) scoring system. Staging of the disease was based on TNM staging system revised in 2010. Results: The median follow-up period was 24 (range: 1-134) months. Recurrence was observed in 24% of the patients in a median 11 (range: 3-96) months. Metastasis was observed in 13% of patients, in the median 15 (range: 1-134 months). The 3-year local control, overall survival and disease-free survival rates were 72%, 59%, and 53%, respectively for all patients. The factors affecting the 3-year local control rates in univariate analysis were performance status (p=0.006), weight loss (p=0.002), localization (p=0.003), and stage (p

Özet

Amaç: Bu çalışmanın amacı baş boyun kanserinde prognostik faktör olarak komorbidite, performans durumu, hemoglobin düzeyi, kilo kaybı, radyoterapiye ara verme ve mukozitin öneminin araştırılmasıdır. Yöntem: Üniversitesimizin Onkoloji Merkezine 2006 ve 2012 tarihleri arasında, baş boyun kanseri tanısı ile tedavi edilen 210 hastanın verileri incelendi. Hastaların performans durumu, hasta başvurusunda Eastern Cooperative Oncology Group (ECOG) skorlama sistemine göre değerlendirildi. Hastalık evresi 2010'da revize edilen TNM evrelemesine göre yapıldı. Bulgular: Hastalar, medyan 24 (dağılım: 1-134) ay takip edildi. Medyan 11 (dağılım: 3-96) ayda hastaların %24'ünde nüks gelişirken, medyan 15 (dağılım: 1-134) ayda %13'ünde uzak metastaz gelişti. Tüm hastalar için 3 yıllık lokal kontrol %72, 3 yıllık genel sağkalım %59, 3 yıllık hastalıksız sağkalım %53 idi. Tek değişkenli analizde hastaların lokal kontrol oranlarını performans durumu (p=0.006), kilo kaybı (p=0.002), hastalık lokalizasyonu (p=0.003), evre (p

🔖

Cite This Article

Yücel, B., Eren, M. F., Atesever, E. A., Kaçan, T., Hasbek, Z., Şeker, M. M. (2013). Prognosis in head and neck cancer: the importance of the patient-, and treatment-related factors. ENT Updates, Cilt: 3 Sayı: 3, 109–115. https://ajindex.com/articles/986848

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statis- tics, 2009. CA Cancer J Clin 2009;59:225-49. Haydaro¤lu A, Bölükbaflı Y, Özsaran Z. Ege Üniversitesi’nde kanser kayıt analizleri: 34134 Olgunun de¤erlendirmesi. Türk Onkoloji Dergisi 2007;22:22-8.
  2. Bourhis J, Overgaard J, Audry H, et al.; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiother- apy in head and neck cancer: a meta-analysis. Lancet 2006;368: 843-54.
  3. Zhang SY, Lu ZM, Luo XN, et al. Retrospective analysis of prog- nostic factors in 205 patients with laryngeal squamous cell carcino- ma who underwent surgical treatment. PLoS One 2013;8:e60157. Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck 2001;23: 566-72.
  4. Montero EH, Trufero JM, Romeo JA, Terré FC. Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori 2008;94:24-9. Taylor SG 4th, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion fol- lowed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-95.
  5. Jones AS, Fenton JE, Husband DJ. Performance data and survival in head and neck cancer. Clin Otolaryngol Allied Sci 2000;25:396- 403. Chang PH, Yeh KY, Huang JS, et al. Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation. Eur Arch Otorhinolaryngol 2013;270:1909-15.
  6. Rades D, Seibold ND, Gebhard MP, Noack F, Schild SE, Thorns C. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 2011;187:626-32. Dische S. Radiotherapy and anemia – the clinical experience. Radiother Oncol 1991;20:35-40.
  7. Rutkowski T, Wygoda A, Skladowski K, et al. Predictors of radio- therapy outcome in patients with T2 supraglottic carcinoma. Eur Arch Otorhinolaryngol 2012;269:923-9. van Acht MJ, Hermans J, Boks DE, Leer JW. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-35.
  8. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglot- tic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-11.
  9. McCloskey SA, Jaggernauth W, Rig